Clinical and genetic drivers of oligo-metastatic disease in colon cancer
•Approximately 10 % of patients with metastatic colon cancer exhibit oligo-metastatic disease (OMD).•Identifying clinical and molecular predictors of OMD is essential for improving the treatment of metastatic colon cancer.•OMD is more commonly associated with male gender and involvement of a single...
Gespeichert in:
Veröffentlicht in: | Neoplasia (New York, N.Y.) N.Y.), 2025-02, Vol.60, p.101111, Article 101111 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Approximately 10 % of patients with metastatic colon cancer exhibit oligo-metastatic disease (OMD).•Identifying clinical and molecular predictors of OMD is essential for improving the treatment of metastatic colon cancer.•OMD is more commonly associated with male gender and involvement of a single organ.•OMD is characterized by lower rates of BRAF p.V600E and KRAS mutations and a higher tumor mutational burden.
Oligo-metastatic disease (OMD) in colon cancer patients exhibits distinct clinical behavior compared to poly-metastatic disease (PMD), with a more responsive and indolent course. This study aims to identify clinical and biological factors uniquely associated with oligo-metastatic behavior.
Metastatic colon cancer patients from an academic center underwent genetic characterization. OMD was defined as ≤3 lesions per organ, each with a total diameter 70 vs. |
---|---|
ISSN: | 1476-5586 1476-5586 |
DOI: | 10.1016/j.neo.2024.101111 |